GIC Discloses Third Change in Shareholding in Ascletis Pharma Inc. -B This Year: Further Increases Stake by Over 10 Million Shares, Raising Holding from 7.00% to 8.36%

HONG KONG, June 26, 2026 - (ACN Newswire) - Recently, Singapore's sovereign wealth fund GIC updated its shareholding data for Ascletis Pharma Inc. -B (01672.HK) once again, marking its third Disclosure of Interests filing in the company this year. According to the filing, compared with the previous DI-registered shareholding of 74,808,000 shares, GIC newly acquired an additional 14,545,000 shares. Following the increase, its shareholding rose from 7.00% to 8.36%, representing another large-scale purchase exceeding 10 million shares. Looking back at the three DI disclosure milestones this year, GIC first crossed the 5% disclosure threshold in February, with its updated DI shareholding reaching 6.42%. After continued accumulation, its second disclosure in May showed that its stake had increased to 7.00%. The latest filing marks GIC's third disclosure update this year, with the institution continuing to make substantial additions to its position. Its total shareholding has further risen to 89,353,000 shares, representing 8.36% of the company.